Hepatocellular carcinoma: a review

J Balogh, D Victor III, EH Asham… - Journal of …, 2016 - Taylor & Francis
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is a
leading cause of cancer-related death worldwide. In the United States, HCC is the ninth
leading cause of cancer deaths. Despite advances in prevention techniques, screening, and
new technologies in both diagnosis and treatment, incidence and mortality continue to rise.
Cirrhosis remains the most important risk factor for the development of HCC regardless of
etiology. Hepatitis B and C are independent risk factors for the development of cirrhosis …

Immunotherapies for hepatocellular carcinoma

JM Llovet, F Castet, M Heikenwalder… - Nature reviews Clinical …, 2022 - nature.com
Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of
patients with HCC receive systemic therapies, traditionally sorafenib or lenvatinib in the first
line and regorafenib, cabozantinib or ramucirumab in the second line. In the past 5 years,
immune-checkpoint inhibitors have revolutionized the management of HCC. The
combination of atezolizumab and bevacizumab has been shown to improve overall survival …